# Spider Versus Emboshield Distal Protection on Cerebral Microembolization During Vulnerable Plaque in Carotid Artery Stenting

Study · id `cardio:ct-nct04904250` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04904250](<https://clinicaltrials.gov/study/NCT04904250>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04904250

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 172 participants.

## Technical summary

Registry record NCT04904250. Randomized; single masking; primary purpose treatment. Start 2022-08-27 (anticipated); primary completion 2024-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 172 participants (planned count; ClinicalTrials.gov record NCT04904250, source copy `cardio:ctgov-nct04904250-2022-06-30`, retrieved 2026-10-26)
- Planned start: 2022-08-27 (anticipated) (ClinicalTrials.gov record NCT04904250, source copy `cardio:ctgov-nct04904250-2022-06-30`, retrieved 2026-10-26)
- Primary completion: 2024-05-31 (anticipated) (ClinicalTrials.gov record NCT04904250, source copy `cardio:ctgov-nct04904250-2022-06-30`, retrieved 2026-10-26)
- Completion: 2024-10-01 (anticipated) (ClinicalTrials.gov record NCT04904250, source copy `cardio:ctgov-nct04904250-2022-06-30`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04904250, source copy `cardio:ctgov-nct04904250-2022-06-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04904250-2022-06-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Spider Versus Emboshield Distal Protection on Cerebral Microembolization During Vulnerable Plaque in Carotid Artery Stenting
- Acronym: CASH-ES
- Condition: Stroke
- Condition: Carotid Stenosis
- Condition: Carotid Artery Stent
- Intervention (Device): Emboshield
- Intervention (Device): Spider
- Lead sponsor: Xuanwu Hospital, Beijing
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Carotid artery stenosis (`cardio:carotid-stenosis`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Xuanwu Hospital, Beijing (`cardio:org-xuanwu-hospital-beijing`)

## Provenance

Content hash: 62bd774c7ffcfdd7f1d8f2c48b5e1598f3c4f25cb20506ad825bdae3545becb2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
